Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 6, 1997, Pages 1037-1040

  Evans, R C ^a   Shim Wong, V ^a   Morris, A I ^a   Rhodes, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; HEPARIN; PREDNISOLONE; SERUM ALBUMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0030816854     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00252.x     Document Type: Article

References (26)

1. Langholz K, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
2. Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet 1991; 337: 238-9.
3. Zavgorodniy LG, Mustgat AP. Application of anticoagulants in the complex treatment of ulcerative colitis. Klin med 1982; 60: 74-80.
4. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90: 220-3.
5. Brazier F, Yzet T, Boruchowicz A, Colombel JF, Duchmann JC, Dupas JL. Treatment of ulcerative colitis with heparin. Gastroenterology 1996; 110: A872(Abstract).
6. Folwaczny C, Spannagl M, Wiebecke W, Jochum M, Heldwein W, Loeschke K. Heparin in the treatment of highly active inflammatory bowel disease. Gastroenterology 1996; 110. A908(Abstract).
7. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995; 37: 585-8.
8. Truelove SC, Wilts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041.
9. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-7.
10. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynaecol 1994; 170: 862-9.
11. Petitou M. Synthetic heparin fragments: New and efficient tools for the study of heparin and its interactions. N Rev Fr Hematol 1984; 26: 221-6.
12. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-6.
13. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides hind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-8.
14. Minter AJ, Keoshkerian E, Chesterman CN, Dawes J. Fibroblast growth factor and heparin protect endothelial cells from the effects of interleukin 1. J Cell Physiol 1996; 167: 229-37.
15. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilised cytokine MIP-1 beta. Nature 1993; 361: 79-82.
16. Gilat D, Hershkoviz R, Mekori YA, Vlodavsky I, Lider O. Regulation of adhesion of CD4+ T lymphocytes to intact or heparinase treated subendothelial extracellular matrix by diffusable or anchored RANTES and MIP-1 beta. J Immunol 1994; 153: 4899-906.
17. Witt DF, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Opinion Biol 1994; 4: 394-400.
18. Volpi N. Inhibition of human leukocyte elastase activity by heparins: influence of charge density. Biochem Biophys Acta 1996; 1290: 299-307.
19. Dwarakanath AD, Finnie IA, Beesley GM, et al. Differential excretion of leucocyte granule components in inflammatory bowel disease: implications for pathogenesis. Clin Sci 1997; 92: 307-13.
20. Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P, Klein NJ. Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 1993; 341: 711-14.
21. Hiebert LM, Wice SM, McDuffie MN, Jacques LB. The heparin target organ - the endothelium. Studies in a rat model. Q J Med 1993; 86: 341-8.
22. Wilson J, Bloom SL, Rhodes JM. Inhibition by heparin of neutrophil adhesion to human intestinal microvascular endothelial cells in vitro. Gut 1996; 39(Suppl.): T147.
23. Korzenik JR. IBD: A vascular disorder? The case for heparin therapy. Inflamm Bowel Dis 1997; 3: 87-94.
24. Dhillon AP, Anthony A, Sim R, et al. Mucosal capilliary thrombi in rectal biopsies. Histopathology 1992; 21: 127-33.
25. Zimmerman G, McIntyre T, Prescolt S. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest 1985; 76: 2235-46.
26. Thompson N, Wakefield A, Pounder R. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-15.